Your response does not refute my observation. If you believe I’ve missed something important then please don’t hesitate to bring it to the attention of this forum.
IMO, the patent granted to Sativex poses a significant intellectual property challenge for IRX, primarily due to issues of prior art. IRX's proposal lacks novelty.
Furthermore, it may be beneficial to consider the outcomes of GW's phase 3 trial. The trial did not meet its primary endpoint, suggesting that the drug may have limited efficacy. This outcome casts doubts on IRX's project, especially since dronabinol is a synthetic version of plant-based THC. While I recognize the advantages of dronabinol in terms of manufacturing and consistency, its mechanism of action remains the same as THC due to their chemical similarity.
Your response does not refute my observation. If you believe...
-
- There are more pages in this discussion • 6 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IRX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
2.8¢ |
Change
0.000(0.00%) |
Mkt cap ! $5.313M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 3009 | 2.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 2.8¢ | 199565 | 3 |
View Market Depth
| Last trade - 16.12pm 25/06/2024 (20 minute delay) ? |
| IRX (ASX) Chart |
Day chart unavailable